Buy CTXR by Nov 3, 2026.

​ Citius Pharmaceuticals recently announced strong commercial progress for LYMPHIR, its FDA-approved cancer treatment for relapsed/refractory cutaneous T-cell lymphoma. New institutions ordering LYMPHIR increased 78% quarter-over-quarter, while institutional vial orders increased 31%. LYMPHIR is now available in 42 institutions, and the company estimates the CTCL market opportunity exceeds $400M. CTXR currently has a $14.10M market cap with 4.98M shares short, representing 18.48% of the float. Fintel shows 7.07 days to cover and a 37.67% borrow rate. Recent volume reached 1.54M …